Health sciences company PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) said on Tuesday that it is preparing to launch clinical trials of cannabinoid sol-gel with the possibility of reducing the transmission of COVID-19 under an expected coronavirus treatment acceleration programme (CTAP).
In conjunction with the COVID-19 sol-gel clinical programme, the company said it has retained Veristat, a global clinical research organization , based in Massachusetts, USA, to assist with planning, designing and developing the clinical trial process and writing the required protocols
However, the company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 at this time.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval